Key Highlights
- Shares of VolitionRx (VNRX) climbed more than 70% during Wednesday’s pre-market session
- VolitionRx announced successful isolation of circulating tumor DNA (ctDNA) at over 99% purity from blood samples
- The breakthrough technology, named Capture-Seq™, employs a dual-step approach combining physical enrichment with advanced bioinformatics
- Blinded study data revealed perfect 49/49 cancer detection in one cohort and 13/14 detection in another
- VolitionRx references a combined addressable market worth approximately $36 billion and is pursuing licensing partnerships
Shares of VNRX experienced a dramatic surge exceeding 70% during Wednesday’s pre-market hours following VolitionRx’s announcement of what the company characterizes as a transformative advancement in liquid biopsy science.
The biotechnology firm revealed it had achieved successful isolation of circulating tumor-derived DNA (ctDNA) from patient blood samples at purity levels surpassing 99%. This achievement means that virtually all non-cancerous DNA was eliminated, producing an exceptionally clean tumor DNA sample.
Liquid biopsy technology has historically faced a fundamental obstacle: the vast majority of cell-free DNA present in bloodstream originates from normal, healthy cells rather than malignant ones. Extracting a reliable cancer signal has proven extraordinarily challenging. VolitionRx claims its innovative approach addresses this critical limitation.
The proprietary methodology, branded as Capture-Seq™, operates through a dual-phase process. Initially, it physically enriches the sample for tumor DNA. Subsequently, sophisticated bioinformatics algorithms eliminate residual background interference. According to the company, this produces a dataset exceeding 99% pure ctDNA.
Chief Scientific Officer Jake Micallef described the achievement as “a world-first.” He explained that CTCF-bound DNA — the particular DNA biomarker this methodology targets — is virtually undetectable in healthy plasma but represents almost exclusively cancer-derived material in patients with malignancies.
“Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long-term goal of liquid biopsy,” Micallef stated in the company’s official announcement.
Blinded Cohort Study Performance
VolitionRx disclosed findings from two separate blinded cohort investigations. The first demonstrated detection of all 49 cancer cases tested. The second identified 13 cancers out of 14 samples.
These figures represent preliminary-stage data, and the study populations are limited in size. More extensive clinical trials will be necessary prior to any potential commercial deployment. Additionally, the methodology captures only a specific fraction of ctDNA, meaning certain tumor DNA fragments may potentially escape detection.
The company has submitted an updated manuscript to Research Square, an academic preprint repository. The research has not yet undergone peer review, which represents a critical validation step before findings gain acceptance within the wider scientific establishment.
Commercial Opportunity and Market Outlook
VolitionRx highlighted a combined total addressable market estimated at roughly $36 billion, encompassing both multi-cancer early detection (MCED) applications and minimal residual disease (MRD) surveillance.
According to the company, it is presently engaged in substantive conversations with prospective diagnostic licensing collaborators. No formal agreements have been disclosed to date.
VNRX shares were positioned to close above their 100-day moving average for the first occurrence since October 8, 2025, assuming pre-market momentum carried through to regular trading hours.
The revised preprint manuscript is anticipated to appear on Research Square in the near term, per the company’s statement.
